首頁 > 市場調查報告書 > 製藥

動物用醫藥

動物用藥品原料藥生產市場規模、佔有率及成長分析（按原料藥類型、動物種類、生產方法、合成方法、應用、最終用戶和地區分類）：產業預測（2026-2033 年）

市場調查報告書

商品編碼

2053985

動物用藥品原料藥生產市場規模、佔有率及成長分析（按原料藥類型、動物種類、生產方法、合成方法、應用、最終用戶和地區分類）：產業預測（2026-2033 年）

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share, and Growth Analysis, By API Type, By Animal Type, By Manufacturing Type, By Synthesis Type, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球動物用藥品原料藥(API) 生產市場價值為 89 億美元，預計到 2033 年將從 2025 年的 95.4 億美元成長到 166.4 億美元，預測期（2026-2033 年）複合年成長率為 7.2%。

動物用藥品原料藥（API）市場的發展主要受獸藥產品需求成長的驅動。這種需求正從基礎感染疾病藥物（AMS）的合理使用以及寵物數量的增加，這些都促使人們更加關注高純度API和多元化的供應鏈，尤其是在印度和中國等國家。製程創新、連續生產和無菌生產的技術進步，在降低成本的同時，也加強了對嚴格GMP標準的遵守。這種充滿活力的環境為契約製造製造商、新創公司和區域生產商創造了機遇，使他們能夠應對各種區域性疾病挑戰。

全球動物用藥品原料藥（API）生產市場的成長要素

寵物數量的成長以及由此帶來的獸醫保健支出增加，顯著提升了對動物用藥品活性成分（API）的需求。寵物飼主越來越傾向於尋求先進的治療方法和預防保健方案，導致對專用配方和活性成分的需求持續成長。這種需求的激增迫使製造商提升產能並創新生產流程。此外，對伴侶動物治療的商業性重視，推動了針對特定需求的寵物飼主的研發，促使企業加強對品管的投入，並加強供應鏈的建設。這些因素共同推動了行業的持續成長，滿足了寵物主人對高效且易於獲取的動物用藥品的不斷變化的需求。

全球動物用藥品原料藥（API）市場限制因素

由於監管要求複雜且不斷變化，全球動物用藥品活性成分生產市場面臨嚴峻挑戰。這些要求給生產商帶來了沉重的耗時耗力負擔，阻礙了新產品的快速上市和業務擴張。嚴格的文件、驗證和合規標準要求生產商對品質系統和監管知識進行大量投資，這對小規模生產商而言尤其沉重。此外，頻繁的監管變化和區域框架的不一致也使全球分銷活動更加複雜，增加了營運風險和管理成本。這些因素最終限制了生產商的靈活性，設定了准入壁壘，並減緩了生產和市場成長的速度。

全球動物用藥品原料藥（API）市場趨勢

全球動物用藥品原料藥（API）市場正呈現出向生物製藥和分子療法顯著轉型的趨勢。這項轉變迫使生產者提升自身能力，超越傳統的小分子合成，進而投資建造用於發酵、細胞培養和下游純化製程的專用基礎設施。各公司日益關注生物製藥API和生物類似藥，以求在競爭中脫穎而出，並積極尋求與生物技術公司建立戰略合作夥伴關係，以加速規模化生產並促進技術轉移。因此，這種不斷變化的市場環境正在重塑開發平臺，除了面臨新的品質和穩定性挑戰外，生物製藥領域的產能建設也日益受到重視。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭格局

前五大公司對比
主要公司的市場定位（2025 年）
主要公司採取的策略
近期市場趨勢
市場佔有率分析：依公司分類（2025 年）
主要公司簡介
- 公司簡介
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 2023-2025年營收年比比較

主要公司簡介

Zoetis Inc.
Elanco Animal Health Incorporated
Merck Animal Health
Boehringer Ingelheim Animal Health
Ceva Sante Animale
Virbac SA
Dechra Pharmaceuticals PLC
Vetoquinol SA
Phibro Animal Health Corporation
Huvepharma EOOD
HIPRA
Indian Immunologicals Limited
Neogen Corporation
Norbrook Laboratories Ltd.
Ourofino Saude Animal
Hester Biosciences Limited
Bimeda Holdings PLC
Kyoritsu Seiyaku Corporation
Ashish Life Science Pvt. Ltd.
SeQuent Scientific Limited

結論與建議

簡介目錄

Product Code: SQMIG35I2694

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market size was valued at USD 8.9 Billion in 2024 and is poised to grow from USD 9.54 Billion in 2025 to USD 16.64 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The veterinary active pharmaceutical ingredient manufacturing market is driven by the increasing demand for animal health products, which has transitioned from basic anti-infectives to advanced biologics and specialty APIs. This sector provides essential molecules for preventing and treating diseases in livestock, companion animals, and aquaculture, critical for ensuring food security and public health. Recent trends include regulatory tightening, antimicrobial stewardship, and growing pet ownership, leading to a focus on higher purity APIs and diversified supply chains, particularly in countries like India and China. Technological advancements in process innovation, continuous processing, and sterile production enhance compliance with stringent GMP standards while minimizing costs. This dynamic environment creates opportunities for contract manufacturing organizations, startups, and regional producers to address diverse localized disease challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Veterinary Active Pharmaceutical Ingredients Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Segments Analysis

Global veterinary active pharmaceutical ingredients manufacturing market is segmented by api type, animal type, manufacturing type, synthesis type, application, end user and region. Based on api type, the market is segmented into Antibiotic APIs, Anti-Inflammatory APIs, Antiparasitic APIs, Vaccine APIs, Hormonal APIs and Others. Based on animal type, the market is segmented into Companion Animals, Livestock Animals, Poultry, Aquaculture Animals and Others. Based on manufacturing type, the market is segmented into Captive Manufacturing and Contract Manufacturing. Based on synthesis type, the market is segmented into Synthetic APIs, Biotech APIs, Fermentation-Based APIs and Others. Based on application, the market is segmented into Infectious Diseases, Pain & Inflammation Management, Parasitic Diseases, Metabolic Disorders and Others. Based on end user, the market is segmented into Veterinary Pharmaceutical Companies, Contract Manufacturing Organizations (CMOs), Veterinary Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market

The rising trend of pet ownership, accompanied by increased spending on animal health, significantly boosts the demand for veterinary active pharmaceutical ingredients (APIs). Pet owners are increasingly seeking advanced therapeutics and preventive care solutions, which in turn drives the consistent need for specialized formulations and active compounds. This escalating demand compels manufacturers to enhance their production capabilities and innovate their manufacturing processes. Additionally, the commercial emphasis on companion animal treatment fosters the development of tailored APIs, encourages investments in quality control, and solidifies supply chain commitments. Together, these dynamics promote ongoing growth in the industry by aligning with the evolving expectations of pet owners for effective and accessible veterinary medicines.

Restraints in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing market faces significant challenges due to intricate and evolving regulatory requirements. These demands impose substantial time and resource burdens on manufacturers, hindering their ability to swiftly introduce new products and expand operations. The necessity for rigorous documentation, validation, and adherence to compliance standards requires extensive investments in quality systems and regulatory knowledge, which can be particularly daunting for smaller producers. Additionally, the frequent alterations in regulations and the inconsistency among different regional frameworks complicate global distribution efforts, increasing operational risks and administrative costs. These factors ultimately limit manufacturers' agility, create barriers to entry, and slow the pace of production and market growth.

Market Trends of the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market

The Global Veterinary Active Pharmaceutical Ingredients Manufacturing market is witnessing a notable trend towards the adoption of biologic and molecular therapies. This shift is prompting manufacturers to enhance their capabilities beyond conventional small molecule synthesis, leading to investments in specialized infrastructure for fermentation, cell culture, and downstream purification. Companies are increasingly focusing on biologic APIs and biosimilars to differentiate themselves, fostering strategic partnerships with biotech firms to accelerate scale-up processes and facilitate knowledge transfer. As a result, this evolving landscape is reshaping research and development pipelines, with a greater emphasis on building competencies in biologics, alongside new quality and stability challenges.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Value Chain Analysis
Case Studies
Technology Assessment
Customer & Buying Criteria Analysis
Pipeline Analysis
Disease Epidemiology

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by API Type & CAGR (2026-2033)

Market Overview
Antibiotic APIs
Anti-Inflammatory APIs
Antiparasitic APIs
Vaccine APIs
Hormonal APIs
Others

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by Animal Type & CAGR (2026-2033)

Market Overview
Companion Animals
Livestock Animals
Poultry
Aquaculture Animals
Others

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by Manufacturing Type & CAGR (2026-2033)

Market Overview
Captive Manufacturing
Contract Manufacturing

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by Synthesis Type & CAGR (2026-2033)

Market Overview
Synthetic APIs
Biotech APIs
Fermentation-Based APIs
Others

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by Application & CAGR (2026-2033)

Market Overview
Infectious Diseases
Pain & Inflammation Management
Parasitic Diseases
Metabolic Disorders
Others

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size by End User & CAGR (2026-2033)

Market Overview
Veterinary Pharmaceutical Companies
Contract Manufacturing Organizations (CMOs)
Veterinary Research Institutes
Others

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size & CAGR (2026-2033)

North America (API Type, Animal Type, Manufacturing Type, Synthesis Type, Application, End User)
- US
- Canada
Europe (API Type, Animal Type, Manufacturing Type, Synthesis Type, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (API Type, Animal Type, Manufacturing Type, Synthesis Type, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (API Type, Animal Type, Manufacturing Type, Synthesis Type, Application, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (API Type, Animal Type, Manufacturing Type, Synthesis Type, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Zoetis Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Elanco Animal Health Incorporated
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim Animal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ceva Sante Animale
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virbac S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dechra Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetoquinol S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Phibro Animal Health Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Huvepharma EOOD
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HIPRA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Indian Immunologicals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neogen Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Norbrook Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ourofino Saude Animal
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hester Biosciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bimeda Holdings PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyoritsu Seiyaku Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ashish Life Science Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SeQuent Scientific Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments